Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.43 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 8/20 | 0.37 |
| ▸ | CES1 | P23141 | 5/20 | 0.36 |
| ▸ | FDPS | P14324 | 4/20 | 0.36 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21505107 | 0.97 | CES2 (0.46) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL15508644 | 0.97 | CES2 (0.46) | CES2LPAR1LPAR3TSHRTHRB | |
| Ammonia Solution, Strong SCHEMBL9443891 | 0.95 | CES2 (0.45) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL15160145 | 0.91 | — | — | |
| SCHEMBL24926244 | 0.88 | CES2 (0.48) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL21004248 | 0.88 | CES2 (0.48) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL21004295 | 0.88 | CES2 (0.48) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL7849144 | 0.83 | CES2 (0.45) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL14479235 | 0.83 | CES2 (0.45) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL14532686 | 0.83 | CES2 (0.45) | CES2LPAR1LPAR3TSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130172558-A1 | NAPROXEN-BASED CHIRAL COMPOUNDS AND LIQUID CRYSTAL DISPLAY APPLICATIONS | CITIZEN FINETECH MIYOTA CO., LTD. (JP) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172558-A1 | NAPROXEN-BASED CHIRAL COMPOUNDS AND LIQUID CRYSTAL DISPLAY APPLICATIONS | CRY1, CRY2, ALOX5 | CES2 217/4885LPAR1 514/4885LPAR3 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.